文献速递关节外科

全髋与全膝关节置换术后两种阿司匹林给药方案的比较

A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties.
PubMed 文献 · J Arthroplasty · 2017-01-24

这项为期1年的前瞻性队列研究纳入643例由单一术者行初次单侧全关节置换的患者,比较阿司匹林325 mg与81 mg每日两次口服用于血栓栓塞预防的短期副作用。结果显示阿司匹林81 mg组的胃肠道不适和恶心发生率显著低于325 mg组,而两组胃肠道出血发生率无显著差异。

要点

  • 阿司匹林325 mg组胃肠道不适和恶心发生率为3.2%(9/282),高于81 mg组的0.8%(3/361),P=.04。
  • 阿司匹林325 mg组胃肠道出血为0.7%(2/282),81 mg组为1.1%(4/361),P=.70,两组无显著差异。
  • 阿司匹林81 mg组1例(0.3%)发生深静脉血栓,无肺栓塞、假体周围感染、耳鸣、喘息和/或气短、胸痛或头痛发生。

核心结论

  • 阿司匹林81 mg每日两次口服与325 mg每日两次口服相比,胃肠道不适和恶心发生率显著更低。
  • 两组胃肠道出血发生率相当,因此无论阿司匹林剂量如何,患者均需被告知这一风险。

研究设计与样本

  • 为期1年的前瞻性队列研究,纳入643例由单一术者行初次单侧全关节置换的患者。
  • 282例患者接受阿司匹林325 mg每日两次口服,361例患者接受阿司匹林81 mg每日两次口服,均用药1个月。
  • 术后1个月发放问卷评估阿司匹林摄入的副作用。

主要发现

  • 胃肠道副作用(胃肠道不适和恶心)总发生率为1.9%,阿司匹林325 mg组为3.2%(9/282),高于81 mg组的0.8%(3/361),P=.04。
  • 胃肠道出血总发生率为0.9%,阿司匹林325 mg组为0.7%(2/282),81 mg组为1.1%(4/361),P=.70。
  • 阿司匹林81 mg组1例(0.3%)发生深静脉血栓。
  • 无患者发生肺栓塞、假体周围感染、耳鸣、喘息和/或气短、胸痛或头痛。
  • 阿司匹林325 mg组9/282(3.2%)停药,81 mg组8/361(2.2%)停药,P=.47;325 mg组4例(1.4%)改为81 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to compare short-term side effects of aspirin (ASA) 325 mg vs ASA 81 mg orally twice daily (PO BID) when used as thromboembolic prophylaxis following primary total joint arthroplasty. METHODS: A 1-year prospective cohort study was performed on 643 primary unilateral total joint arthroplasty patients operated on by a single surgeon. Two hundred eighty-two patients were administered ASA 325 mg PO BID and 361 patients were administered ASA 81 mg PO BID for 1 month. A questionnaire assessing the side effects of ASA intake was administered 1 month postoperatively. RESULTS: The overall rate of gastrointestinal side effects (GI upset and nausea) was 1.9%, but ASA 325 mg had a higher rate 9/282 (3.2%) than ASA 81 mg 3/361 (0.8%), P = .04. Overall GI bleeding was 0.9%, with 2/282 (0.7%) in the ASA 325 mg group, vs 4/361 (1.1%) in the ASA 81 mg group, P = .70. One patient in the ASA 81 mg group (0.3%) developed a deep vein thrombosis. No patient developed pulmonary embolism, periprosthetic joint infection, tinnitus, wheezing and/or shortness of breath, chest pain, or headaches. In the ASA 325 mg group, 9/282 (3.2%) discontinued ASA and in the ASA 81 mg group, 8/361 (2.2%) discontinued ASA, P = .47. Four patients in the ASA 325 group (1.4%) changed to ASA 81 mg. CONCLUSION: ASA 81 mg is associated with significantly less GI distress and nausea compared with ASA 325 mg. GI bleeding was equally prevalent between the 2 dosing regimens, so patients need to be informed of this risk regardless of the ASA dose.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Feldstein MJ, Low SL, Chen AF, et al. A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties. J Arthroplasty. 2017. PMID: 28214257. doi:10.1016/j.arth.2017.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。